Trading for the first 4 months of the year is reported to be slightly ahead of expectations, up 9% YoY to £9.3m. This has been driven by a recovery in activity levels in the Clinical business and a stronger than expected performance from sales into the Research market. Costs remain tightly controlled and the business traded at close to EBITDA breakeven in the period (pre-HO costs). We make no changes to forecasts at this stage, but view this as a highly encouraging update. We continue to see a s ....
21 May 2021
Encouraging trading YTD
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Encouraging trading YTD
NIOX Group Plc (NIOX:LON) | 67.2 0.8 1.8% | Mkt Cap: 284.1m
- Published:
21 May 2021 -
Author:
Chris Glasper | Edward Thomason -
Pages:
3
Trading for the first 4 months of the year is reported to be slightly ahead of expectations, up 9% YoY to £9.3m. This has been driven by a recovery in activity levels in the Clinical business and a stronger than expected performance from sales into the Research market. Costs remain tightly controlled and the business traded at close to EBITDA breakeven in the period (pre-HO costs). We make no changes to forecasts at this stage, but view this as a highly encouraging update. We continue to see a s ....